Skip to Content
Merck
All Photos(2)

Documents

SML3800

Sigma-Aldrich

Selumetinib

≥98% (HPLC)

Synonym(s):

5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, ARRY 142886, ARRY-142886, ARRY142886, AZD 6244, AZD-6244, AZD6244

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C17H15BrClFN4O3
CAS Number:
606143-52-6
Molecular Weight:
457.68
MDL number:
MFCD11977472
UNSPSC Code:
12352200
NACRES:
NA.21

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

2-8°C

Biochem/physiol Actions

Selumetinib (ARRY-142886; AZD6244) is an orally active, potent and selective MEK1/2 inhibitor (MEK1 IC50 = 14 nM; <20% inhibition of >40 other kinases at 10 µM) that effectively downregulates cellular ERK1/2 phosphorylation levels (IC50 <40 nM post 1h incubation using 5 different cell lines). Selumetinib inhibits MEK1/2-dependent proliferations in cancer cultures (IC50 in nM = 59/Malme-3M, 93/SK-MEL-28, 175/HT-29, 200/SK-MEL-2, 473/MIA PaCa-2) and exhibits anti-tumor efficacy in mice in vivo (10-100 mg/kg p.o. b.i.d.; BxPC3 & HT-29 xenograft models).

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H317,H361f,H373,H413

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Repr. 2 - Skin Sens. 1 - STOT RE 2

Target Organs

Gastrointestinal tract,Eyes,Urinary tract

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Barry R Davies et al.
Molecular cancer therapeutics, 6(8), 2209-2219 (2007-08-19)
Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often associated with mutational activation of BRAF or RAS. MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are
Nikolas K Haass et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(1), 230-239 (2008-01-04)
Disseminated melanoma is highly therapy resistant. The finding that 66% of melanomas harbor the activating BRAF(V600E) mutation has raised expectations for targeting the Ras/RAF/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathway in melanoma. This study addresses the anti-melanoma activity
Tammie C Yeh et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(5), 1576-1583 (2007-03-03)
The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service